IBO AMEX
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Houston, TX 77084
US
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| DSS, INC. | S-Sale | 156 | $7.06 | 2026-09-24 |
| DSS, INC. | S-Sale | 27 | $6.95 | 2026-09-23 |
| Macko Todd D | S-Sale | 43,400 | $0.56 | 2026-03-27 |
| Macko Todd D | S-Sale | 1,600 | $0.60 | 2026-03-25 |
| Grady Jason | S-Sale | 50,000 | $0.65 | 2026-03-23 |